You just read:

Biscayne Readies Phase 1b Trial for Novel Antiepileptic Agent BIS-001 and Receives FDA Orphan Drug Designation for Dravet Syndrome

News provided by

Biscayne Neurotherapeutics, Inc.

May 09, 2017, 07:00 ET